Vasopressin for refractory persistent pulmonary hypertension of the newborn in preterm neonates – a case series

References

• Murphy JD, Rabinovitch M, Goldstein JD, et al. The structural basis of persistent pulmonary hypertension of the newborn infant. J Pediatr. 1981;98(6):962–967.
   PubMed Web of Science ®Google Scholar
• Walsh-Sukys MC, Tyson JE, Wright LL, et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics. 2000;105(1):14–20.
   PubMed Web of Science ®Google Scholar
• Konduri GG, Vohr B, Robertson C, et al. Early inhaled nitric oxide therapy for term and near-term newborn infants with hypoxic respiratory failure: neurodevelopmental follow-up. J Pediatr. 2007;150(3):235–240.
   PubMed Web of Science ®Google Scholar
• Ellsworth MA, Harris MN, Carey WA, et al. Off-label use of inhaled nitric oxide after release of NIH consensus statement. Pediatrics. 2015;135(4):643–648.
   PubMed Web of Science ®Google Scholar
• Evans N. Current controversies in the diagnosis and treatment of patent ductus arteriosus in preterm infants. Adv Neonatal Care. 2003;3(4):168–177.
   PubMedGoogle Scholar
• Baczynski M, Ginty S, Weisz DE, et al. Short-term and long-term outcomes of preterm neonates with acute severe pulmonary hypertension following rescue treatment with inhaled nitric oxide. Arch Dis Child Fetal Neonatal Ed. 2017;102(6):F508–F614.
   PubMed Web of Science ®Google Scholar
• Mohamed A, Nasef N, Shah V, et al. Vasopressin as a rescue therapy for refractory pulmonary hypertension in neonates: case series. Pediatr Crit Care Med. 2014;15(2):148–154.
   PubMed Web of Science ®Google Scholar
• McNamara PJ, Laique F, Muang-In S, et al. Milrinone improves oxygenation in neonates with severe persistent pulmonary hypertension of the newborn. J Crit Care. 2006;21(2):217–222.
   PubMed Web of Science ®Google Scholar
• Steinhorn RH, Kinsella JP, Pierce C, et al. Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension. J Pediatr. 2009;155(6):841–847 e1.
   PubMed Web of Science ®Google Scholar
• James AT, Bee C, Corcoran JD, et al. Treatment of premature infants with pulmonary hypertension and right ventricular dysfunction with milrinone: a case series. J Perinatol. 2015;35(4):268–273.
   PubMed Web of Science ®Google Scholar
• Bidegain M, Greenberg R, Simmons C, et al. Vasopressin for refractory hypotension in extremely low birth weight infants. J Pediatr. 2010;157(3):502–504.
   PubMed Web of Science ®Google Scholar
• Ikegami H, Funato M, Tamai H, et al. Low-dose vasopressin infusion therapy for refractory hypotension in ELBW infants. Pediatr Int. 2009;52(3):368–373.
   PubMed Web of Science ®Google Scholar
• Meyer S, Gottschling S, Baghai A, et al. Arginine-vasopressin in catecholamine-refractory septic versus non-septic shock in extremely low birth weight infants with acute renal injury. Crit Care. 2006;10(3):R71.
   PubMed Web of Science ®Google Scholar
• Siehr SL, Feinstein JA, Yang W, Peng LF, et al. Hemodynamic effects of phenylephrine, vasopressin, and epinephrine in children with pulmonary hypertension: a pilot study. Pediatr Crit Care Med. 2016;17(5):428–437.
   PubMed Web of Science ®Google Scholar
• Patel BM, Chittock DR, Russell JA, et al. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology. 2002;96(3):576–582.
   PubMed Web of Science ®Google Scholar
• Dunser MW, Mayr AJ, Stallinger A, et al. Cardiac performance during vasopressin infusion in postcardiotomy shock. Intensive Care Med. 2002;28(6):746–751.
   PubMed Web of Science ®Google Scholar
• Biban P, Gaffuri M. Vasopressin and terlipressin in neonates and children with refractory septic shock. Curr Drug Metab. 2013;14(2):186–192.
   PubMed Web of Science ®Google Scholar
• Malikiwi A, Sasi A, Tan K, et al. Vasopressin as an adjunct therapy for pulmonary hypertension: a case report. Eur J Pediatr. 2014;173(12):1651–1654.
   PubMed Web of Science ®Google Scholar
• Stathopoulos L, Nicaise C, Michel F, et al. Terlipressin as rescue therapy for refractory pulmonary hypertension in a neonate with a congenital diaphragmatic hernia. J Pediat Surg. 2011;46(2):e19–21.
   PubMed Web of Science ®Google Scholar
• Hansmann G, Koestenberger M, Alastalo TP, et al. 2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT. J Heart Lung Transplant. 2019;38(9):879–901.
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics. Committee on Fetus and Newborn. Use of inhaled nitric oxide. Pediatrics. 2000;106(2 Pt 1):344–345.
   PubMed Web of Science ®Google Scholar
• Kelly LE, Ohlsson A, Shah PS. Sildenafil for pulmonary hypertension in neonates. Cochr Database Syst Rev. 2017;8:CD005494.
   PubMed Web of Science ®Google Scholar
• Maneenil G, Thatrimontrichai A, Janjindamai W, et al. Effect of bosentan therapy in persistent pulmonary hypertension of the newborn. Pediatr Neonatol. 2018;59(1):58–64.
   PubMed Web of Science ®Google Scholar
• Abman SH, Hansmann G, Archer SL, et al. Pediatric pulmonary hypertension: guidelines from the American Heart Association and American Thoracic Society. Circulation. 2015;132(21):2037–2099.
   PubMed Web of Science ®Google Scholar
• Sasi A, Sehgal A. Use of inhaled nitric oxide in preterm infants: a regional survey of practices. Heart Lung. 2014;43(4):347–350.
   PubMed Web of Science ®Google Scholar
• Soraisham AS, Harabor A, Shivananda S, et al. Trends and variations in the use of inhaled nitric oxide in preterm infants in canadian neonatal intensive care units. Am J Perinatol. 2016;33(07):715–722.
   PubMedGoogle Scholar
• Finer NN, Evans N. Inhaled nitric oxide for the preterm infant: evidence versus practice. Pediatrics. 2015;135(4):754–756.
   PubMed Web of Science ®Google Scholar
• Kumar P. Use of inhaled nitric oxide in preterm infants. Pediatrics. 2014;133(1):164–170.
   PubMed Web of Science ®Google Scholar
• Carey WA, Weaver AL, Mara KC, et al. Inhaled nitric oxide in extremely premature neonates with respiratory distress syndrome. Pediatrics. 2018;141(3):e20173108.
   PubMed Web of Science ®Google Scholar
• Jain A, McNamara PJ. Persistent pulmonary hypertension of the newborn: advances in diagnosis and treatment. Semin Fetal Neonat Med. 2015;20(4):262–271.
   PubMed Web of Science ®Google Scholar
• Rudichenko VM, Beierwaltes WH. Arginine vasopressin-induced renal vasodilation mediated by nitric oxide. J Vasc Res. 1995;32(2):100–105.
   PubMed Web of Science ®Google Scholar
• Eichinger MR, Walker BR. Enhanced pulmonary arterial dilation to arginine vasopressin in chronically hypoxic rats. Am J Physiol. 1994;267(6):H2413–9.
   PubMedGoogle Scholar
• Gold JA, Cullinane S, Chen J, et al. Vasopressin as an alternative to norepinephrine in the treatment of milrinone-induced hypotension. Crit Care Med. 2000;28(1):249–252.
   PubMed Web of Science ®Google Scholar
• Chen JM, Cullinane S, Spanier TB, et al. Vasopressin deficiency and pressor hypersensitivity in hemodynamically unstable organ donors. Circulation. 1999;100(Supplement 2):II-244–246.
   Google Scholar
• Suzuki Y, Satoh S, Oyama H, et al. Regional differences in the vasodilator response to vasopressin in canine cerebral arteries in vivo. Stroke. 1993;24(7):1049–1053 (discussion 53-4).
   PubMed Web of Science ®Google Scholar
• Holmes CL, Walley KR, Chittock DR, et al. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med. 2001;27(8):1416–1421.
   PubMed Web of Science ®Google Scholar